124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1878-1885

  O'Donoghue, Joseph A ^a   Smith Jones, Peter M ^a   Humm, John L ^a   Ruan, Shutian ^a   Pryma, Daniel A ^a   Jungbluth, Achim A ^a   Divgi, Chaitanya R ^a   Carrasquillo, Jorge A ^a   Pandit Taskar, Neeta ^a   Fong, Yuman ^a   Strong, Vivian E ^a   Kemeny, Nancy E ^a   Old, Lloyd J ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

124I; Colorectal cancer; HuA33; Immuno PET; Radioimmunotherapy

Indexed keywords

CANCER ANTIBODY; HUMANIZED A33 ANTIBODY I 124; IODINE 124; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GPA33 PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; AGED; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; ANIMAL; CLINICAL TRIAL; COLORECTAL TUMOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN TRANSPORT; SCINTISCANNING;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTORADIOGRAPHY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTEIN TRANSPORT;

EID: 83755168354     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.095596     Document Type: Article

References (36)

1. Garinchesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996;9:465-471. (Pubitemid 26323936)
2. Johnstone CN, White SJ, Tebbutt NC, et al. Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem. 2002;277:34531-34539.
3. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol. 2000;46:S27-S32.
4. Heath JK, White SJ, Johnstone CN, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1997;94:469-474. (Pubitemid 27053657)
5. Ackerman ME, Chalouni C, Schmidt MM, et al. A33 antigen displays persistent surface expression. Cancer Immunol Immunother. 2008;57:1017-1027.
6. Johnstone CN, Tebbutt NC, Abud HE, et al. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G500-G510.
7. Almqvist Y, Orlova A, Sjostrom A, et al. In vitro characterization of At-211-labeled antibody A33: a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother Radiopharm. 2005;20:514-523. (Pubitemid 41619143)
8. Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A. In vitro and in vivo characterization of Lu-177-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol. 2006;33:991-998. (Pubitemid 44791957)
9. Deckert PM, Bornmann WG, Ritter G, et al. Specific tumour localisation of a huA33 antibody: carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Int J Oncol. 2004;24:1289-1295.
10. Coelho V, Dernedde J, Petrausch U, et al. Design, construction, and in vitro analysis of A33scFv: CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Int J Oncol. 2007;31:951-957.
11. Cortez C, Tomaskovic-Crook E, Johnston APR, et al. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells. ACS Nano. 2007;1:93-102.
12. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal-antibody A33 in patients with advanced colon-cancer. J Clin Oncol. 1994;12:1561-1571. (Pubitemid 24244990)
13. Welt S, Scott A, Divgi C, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787-1797. (Pubitemid 26187992)
14. King DJ, Antoniw P, Owens RJ, et al. Preparation and preclinical evaluation of humanized A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72:1364-1372. (Pubitemid 26002644)
15. Ritter G, Cohen LS, Williams C, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 2001;61:6851-6859. (Pubitemid 32896510)
16. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-124-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310. (Pubitemid 46464522)
17. Pentlow KS, Graham MC, Lambrecht RM, Cheung NKV, Larson SM. Quantitative imaging of I-124 using positron emitting tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys. 1991;18:357-366.
18. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557-1562. (Pubitemid 26321647)
19. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.
20. United States Pharmacopeial Convention, Inc. Pharmaceutical compounding-sterile preparations. USP 〈797〉. First Supplement to The United Stated Pharmacopeia, 27th rev.; and The National Formulary, 22nd ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2004.
21. Fraker PJ, Speck JC. Protein and cell-membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3A,6A-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857. (Pubitemid 8305904)
22. Zar JH. Biostatistical Analysis. Fifth ed. Upper Saddle River, NJ: Prentice Hall; 2010.
23. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-1497. (Pubitemid 17028574)
24. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides - beta-dosimetry of small spheres. Phys Med Biol. 1994;39:961-981.
25. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.
26. Chong G, Lee F, Hopkins W, et al. Phase I trial of I-131-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818-4826. (Pubitemid 41568168)
27. Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810-4817. (Pubitemid 41568167)
28. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med. 2003;44:400-411. (Pubitemid 39586017)
29. Forero A, Weiden PL, Vose JM, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004;104:227-236. (Pubitemid 38879862)
30. Green DJ, Pagel JM, Pantelias A, et al. Pretargeted radioimmunotherapy for B-Cell lymphomas. Clin Cancer Res. 2007;13:5598s-5603s. (Pubitemid 47510393)
31. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 2008;68:4819-4826.
32. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med. 1996;37:1052-1057. (Pubitemid 126447149)
33. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895. (Pubitemid 36254544)
34. Sato N, Hassan R, Axworthy DB, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med. 2005;46:1201-1209. (Pubitemid 43741083)
35. Förster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med. 2006;47:140-149. (Pubitemid 46768523)
36. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004;19:378-387. (Pubitemid 38924504)